US Pharma MarketingThe British biotechnology startup is making "pan-gamma delta” T cell engagers it says can address the limitations of similar, existing therapies.
Cytospire hauls in $83M for a new type of T cell engager
<p>The British biotechnology startup is making "pan-gamma delta” T cell engagers it says can address the limitations of similar, existing therapies. </p>
Source: BioPharma Dive